ASX:PAB - Patrys Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 06/18/2019 10:38 AM ET)
Today's Range
Now: A$0.03
50-Day Range
MA: A$0.02
52-Week Range
Now: A$0.03
Volume157,716 shs
Average VolumeN/A
Market Capitalization$27.83 million
P/E RatioN/A
Dividend YieldN/A
Patrys Limited, a biopharmaceutical company, develops products for the treatment of cancer in Australia. The company develops PAT-SM6, a natural human antibody that is in Phase I/IIa clinical trials used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers, such as multiple myeloma; and PAT-SC1, a clinical trial antibody that treats gastric cancer. It also develops PAT-LM1, a natural human antibody that is used for the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10, a lupus autoantibody that penetrates live cell nuclei by binding to DNA or its precursors outside of cells and then following it into cell nuclei through a nucleoside transporter. The company was founded in 2006 and is based in South Melbourne, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 3 9692 7222



Sales & Book Value

Annual Sales$514,365.00
Cash FlowA$0.01 per share
Book ValueA$0.01 per share



Outstanding Shares1,070,249,984
Market Cap$27.83 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PAB News and Ratings via Email

Sign-up to receive the latest news and ratings for PAB and its competitors with MarketBeat's FREE daily newsletter.

Patrys (ASX:PAB) Frequently Asked Questions

What is Patrys' stock symbol?

Patrys trades on the ASX under the ticker symbol "PAB."

Has Patrys been receiving favorable news coverage?

News coverage about PAB stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Patrys earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Patrys.

Who are some of Patrys' key competitors?

Who are Patrys' key executives?

Patrys' management team includes the folowing people:
  • Dr. James A. Campbell Ph.D., MBA, MD, CEO & Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 46)
  • Dr. Deanne Greenwood GAICD, Ph.D., MBA, VP of Bus. Devel. & Intellectual Property

What is Patrys' stock price today?

One share of PAB stock can currently be purchased for approximately A$0.03.

How big of a company is Patrys?

Patrys has a market capitalization of $27.83 million and generates $514,365.00 in revenue each year. View Additional Information About Patrys.

What is Patrys' official website?

The official website for Patrys is

How can I contact Patrys?

The company can be reached via phone at 61 3 9692 7222.

MarketBeat Community Rating for Patrys (ASX PAB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about Patrys and other stocks. Vote "Outperform" if you believe PAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by Staff

Featured Article: Day Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel